References

Multiple studies demonstrate Guardant Infinity’s
high specificity and sensitivity for methylation-based
MRD detection
without requiring up-front tissue1-3

Trial


COSMOS

TRACER

QUANTIFY CANCER

New studies support
methylation-based ctDNA detection
with Guardant Infinity after curative
intent therapy.1-3


SUCCESS-A

ctDNA, circulating tumor DNA; MRD, minimal residual disease.

Indication

Stage II/III
colon cancer

Early-stage
breast cancer

Early-stage
breast cancer


Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma